Anzeige
Mehr »
Freitag, 12.06.2026 - Börsentäglich über 12.000 News
BTQ 73x. Kommt jetzt Delta?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1T87A | ISIN: US45408X3089 | Ticker-Symbol: IGS1
Tradegate
11.06.26 | 21:50
0,242 Euro
-1,63 % -0,004
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
IGC PHARMA INC Chart 1 Jahr
5-Tage-Chart
IGC PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,2420,25007:40
0,2420,25007:30

Aktuelle News zur IGC PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoIGC Pharma, Inc.: IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis390Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses POTOMAC, MD / ACCESS Newswire /...
► Artikel lesen
IGC PHARMA Aktie jetzt für 0€ handeln
DiIGC Pharma, Inc.: Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts285POTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease,...
► Artikel lesen
MoIGC Pharma, Inc. - 8-K, Current Report4
02.06.IGC Pharma, Inc.: IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis305Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis POTOMAC, MD / ACCESS Newswire / June 2, 2026 / IGC Pharma...
► Artikel lesen
19.05.IGC Pharma, Inc.: IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment548- Continued Advancement of CALMA Phase 2 Trial - POTOMAC, MD / ACCESS Newswire / May 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company...
► Artikel lesen
19.05.IGC Pharma GAAP EPS of -$0.02 in-line, revenue of $0.32M beats by $0.09M3
15.05.IGC Pharma, Inc.: IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference335Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development. POTOMAC, MD / ACCESS Newswire / May 15, 2026...
► Artikel lesen
28.04.IGC Pharma, Inc.: IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase463Outreach initiative supports awareness of agitation and patient engagement as enrollment approaches completion POTOMAC, MD / ACCESS Newswire / April 28, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC"...
► Artikel lesen
22.04.IGC Pharma, Inc.: IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion386Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study POTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. (NYSE American:IGC)...
► Artikel lesen
20.04.IGC Pharma, Inc. - 8-K, Current Report3
20.04.IGC Pharma, Inc.: IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia351Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completion POTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC Pharma...
► Artikel lesen
14.04.IGC Pharma, Inc.: IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout389POTOMAC, MD / ACCESS Newswire / April 14, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical...
► Artikel lesen
11.04.New to The Street Broadcasts on Bloomberg Television at 6:30 PM EST Featuring IGC Pharma, Vivos Therapeutics, Acurx Pharmaceuticals, and Equinox Gold1.215Special continuing M&A Segment with Senior M&A Partner at Sullivan & Cromwell LLP, Frank Aquila NEW YORK CITY, NY / ACCESS Newswire / April 11, 2026 / New to The Street announces its latest nationally...
► Artikel lesen
08.04.IGC Pharma, Inc.: Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts435POTOMAC, MD / ACCESS Newswire / April 8, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA...
► Artikel lesen
07.04.IGC Pharma, Inc.: IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease300POTOMAC, MD / ACCESS Newswire / April 7, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing innovative treatments for Alzheimer's...
► Artikel lesen
30.03.IGC Pharma, Inc. - 8-K, Current Report-
30.03.IGC Pharma, Inc.: IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness298POTOMAC, MD / ACCESS Newswire / March 30, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease...
► Artikel lesen
25.03.New to The Street and IGC Pharma Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning289NEW YORK, NY / ACCESS Newswire / March 25, 2026 / New to The Street, a premier financial media platform known for its national television distribution and integrated investor engagement strategy, today...
► Artikel lesen
19.03.IGC Pharma reports results7
19.03.IGC Pharma, Inc.: IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025549- Strategic Pivot to Pure-Play Biotech - POTOMAC, MD / ACCESS Newswire / March 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing...
► Artikel lesen
Weiter >>
66 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1